The stock is a binary catalyst play on SUPRAME topline (H1 2027). The slower-than-expected event accumulation introduces uncertainty but does not alter the final PFS analysis timeline. The planned enrollment increase for OS power is a positive for commercial profile but adds trial cost. Cash reach into 2028 provides buffer. Near-term price action will be driven by pipeline updates at ESMO in fall 2026. Consider scaling into any weakness ahead of ESMO data.
Drugs in focus
IMTX drug pipeline →IMA203
▲ Bullish Named in this 6-K- Impact
- Phase
- Phase 3
- Time to market
- If Phase 3 succeeds, BLA submission is planned for 2027 with a potential commercial launch in 2027-2028.
- Next catalyst
- None dated
What to watchThe binary catalyst is the SUPRAME Phase 3 final PFS readout in H1 2027. Positive data would validate anzu-cel for BLA submission in 2027 and could drive significant upside toward analyst targets (~$17). A negative or underwhelming result would likely hit the stock hard given its current single-asset weighting. Interim operational updates on enrollment could come at the Q3 earnings call on Nov 16, 2026.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 18 $9.09entry
- T+1 · 3mo ago +1.76%α +1.55% · $9.25
- T+5 · 3mo ago +1.65%α +1.85% · $9.24
- T+20 · 2mo ago −2.97%α −1.98% · $8.82
- T+60 · 6d ago −29.37%α −27.33% · $6.42
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Immatics reported Q2 2026 financial results showing a net loss of €62.5M ($71.2M) on collaboration revenue of €9.1M ($10.4M), with R&D expenses rising sharply to €62.4M ($71.1M) as the Phase 3 SUPRAME trial accelerates. Enrollment remains on track to complete by year-end, but PFS events are occurring slower than modeled, prompting a streamlined final analysis (topline H1 2027) and adding ~90 patients for OS power. Cash and financial assets stood at €393.4M ($448.2M), projected into 2028.
Key Facts
- Q2 2026 revenue: €9.1M ($10.4M) from collaboration agreements (Moderna €6.5M, BMS €2.7M)
- Q2 2026 net loss: €62.5M ($71.2M), improved from €70.3M ($80.1M) in Q2 2025
- Cash and financial assets: €393.4M ($448.2M) as of June 30, 2026; cash reach projected into 2028
- SUPRAME enrollment on track to complete randomizations by year-end; PFS events occurring slower than modeled
- Company plans streamlined final PFS analysis (topline H1 2027) with 90% power, adding ~90 patients for OS
- BLA submission planned in 2027 following PFS topline
- Phase 1b anzu-cel data at ASCO 2026: 56% cORR, 14.6 mo mDOR, 6.1 mo mPFS, 16.2 mo mOS in melanoma
- IMA203CD8 Phase 1 data in gynecologic cancers: 63% ORR, 50% cORR at clinically relevant doses
- IMA402 bispecific Phase 1b data at RP2D range expected at ESMO 2026
- First patient dosed in Moderna collaboration trial (mRNA-4200) in July 2026, triggering milestone payment
- R&D expenses Q2 2026: €62.4M (up 38% YoY from €45.1M), driven by SUPRAME trial costs
- Net cash used in operations H1 2026: €102.5M vs €73.3M in H1 2025
Financial Impact
Net loss of €62.5M in Q2 2026, operating cash burn of €102.5M in H1 2026, cash runway into 2028
Risk Factors
- SUPRAME PFS topline data (H1 2027) could miss expectations if slower event rate signals lower separation from standard of care
- R&D burn is accelerating (€121.6M in H1 2026 vs €87.0M in H1 2025) with no near-term product revenue
- Competitive landscape for cell therapies in melanoma (lifileucel, RP1, etc.) could narrow market opportunity
- Reliance on collaboration revenue (Moderna, BMS) for near-term cash flow
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-354715 |
| Document: imtx-ex99_2.htm | 0001193125-26-354715 |
| Document: imtx-20260630.htm | 0001193125-26-354715 |
| Document: imtx-ex99_3.htm | 0001193125-26-354715 |
| Document: 0001193125-26-354715-index-headers.html | 0001193125-26-354715 |
| Document: 0001193125-26-354715-index.html | 0001193125-26-354715 |
| Document: 0001193125-26-354715.txt | 0001193125-26-354715 |
Track record
23 reports on IMTX
8 of 14 bullish or bearish reports moved the stock their way by T+5. Best: +22.12% at T+20 after the May 12, 2026 report. 9 of 14 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $6.24 Now $6.17 −1.12% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $6.55 Now $6.17 −5.73% settles Nov 23
- Nov 10, 20266d ago 6-K Neutral 5/10 No price data
- Nov 10, 20266d ago Press Release Neutral 4/10 Entry $6.42 Now $6.17 −3.89% settles Nov 17
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $7.15 to $7.20 Now $6.17 −13.71% ▲ +0.70% +1.96% vs SPY
- Oct 24, 202624d ago Press Release Bullish 6/10 Entry $7.15 to $7.20 Now $6.17 −13.71% ▲ +0.70% +1.96% vs SPY
- Oct 23, 202624d ago 6-K Bullish 7/10 Entry $7.31 to $7.20 Now $6.17 −15.60% ▼ −1.50% −0.95% vs SPY
- Aug 27, 202611w ago Insider Buy Bullish 6/10 Entry $9.45 to $9.56 Now $6.17 −34.71% ▲ +1.16% +1.05% vs SPY
- Aug 26, 202611w ago 6-K Bearish 6/10 Entry $9.36 to $9.46 Now $6.17 +34.08% ▼ −1.07% −0.80% vs SPY
- Aug 18, 202612w ago 6-K Neutral 6/10 Viewing Entry $9.09 to $9.24 Now $6.17 −32.12% ▲ +1.65% +1.85% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers